lyophilised powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Gly-His-Lys | Tripeptide; copper binds via His and N-terminus |
| Copper stoichiometry | Typically 1 Cu(II) per peptide | Can form ternary complexes under some conditions |
| Molecular formula (peptide) | C14H24N6O4 | Free peptide; copper complex mass differs |
| Appearance (solid) | Blue to blue-green powder | Color derives from copper d-d transitions |
| Solubility | Soluble in water and polar solvents | Solubility depends on pH and counterions |
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
Trump emphasized that European nations should shoulder the primary burden of assistance and pressed Ukrainian president Volodymyr Zelenskyy to take greater responsibility in securing peace. He further hinted that Ukraine may eventually face difficult choices, including potential territorial concessions, to bring the conflict to an end. In September 2025, Trump urged Europe to stop buying Russian oil and start putting economic pressure on China for funding Russia's war effort. Treasury Secretary Scott Bessent said the Trump administration is "prepared to increase pressure on Russia, but we need our European partners to follow us". In September 2025, the Trump administration approved the delivery of the first two packages of weapons to Ukraine from US stockpiles totalling approximately $1 billion, which would be paid for by NATO allies, under the new mechanism called Prioritized Ukraine Requirements List (PURL). The mechanism aims to deliver aid worth up to $10 billion. On September 27, 2025, President Zelenskyy announced a $90 billion arms agreement with the United States in works. On October 22, 2025, the United States imposed sanctions on Russian energy companies Rosneft and Lukoil, affecting their customers in China and India. In November 2025, Trump proposed a peace plan that would require Ukraine to cede territory in the Donbas, including Ukrainian-controlled parts of Donetsk Oblast. The plan would also freeze the front lines in Kherson Oblast and Zaporizhzhia Oblast.
==== G. The cartilaginous pyramid of the nose ==== The cartilaginous septum (septum nasi) extends from the nasal bones in the midline (above) to the bony septum in the midline (posteriorly), then down along the bony floor. The septum is quadrangular; the upper half is flanked by two triangular-to-trapezoidal cartilages: the upper lateral-cartilages, which are fused to the dorsal septum in the midline, and laterally attached, with loose ligaments, to the bony margin of the pyriform (pear-shaped) aperture, while the inferior ends of the upper lateral-cartilages are free (unattached). The internal area (angle), formed by the septum and upper lateral-cartilage, constitutes the internal valve of the nose; the sesamoid cartilages are adjacent to the upper lateral-cartilages in the fibroareolar connective tissue. Beneath the upper lateral-cartilages lay the lower lateral-cartilages; the paired lower lateral-cartilages swing outwards, from medial attachments, to the caudal septum in the midline (the medial crura) to an intermediate crus (shank) area. Finally, the lower lateral-cartilages flare outwards, above and to the side (superolaterally), as the lateral crura; these cartilages are mobile, unlike the upper lateral cartilages. Furthermore, some persons present anatomical evidence of nasal scrolling—i.e., an outward curving of the lower borders of the upper lateral-cartilages, and an inward curving of the cephalic borders of the alar cartilages.
== Airlines and destinations == In 2025, Hohhot Baita International Airport plans to operate 139 routes, serving 92 cities in total, including 83 nonstop destinations and 6 international or regional cities.
==== Corneal Allogenic Intrastromal Ring Segments (CAIRS) ==== Corneal Allogenic Intrastromal Ring Segments Keratoplasty (CAIRS Keratoplasty) represent an innovative surgical approach for the management of keratoconus, utilizing donor corneal tissue as biocompatible implants to reshape the ectatic cornea and improve visual acuity. CAIRS is a corneal transplant and due to its success rate, efficacy, safety profile and use of biologic tissue, it been recognised as such by funding bodies in Australia, the United Kingdom, Brazil, Japan, the Netherlands, Germany and numerous other countries. Unlike traditional synthetic intrastromal corneal ring segments (ICRS), which are typically made from polymethyl methacrylate (PMMA), CAIRS keratoplasty employs preserved allogeneic donor cornea to minimize risks such as extrusion, infection, or foreign body reactions associated with non-biological materials. The technique was developed by Soosan Jacob, who first described CAIRS in 2018 in a prospective interventional case series published in the Journal of Refractive Surgery. In this study, 24 eyes of 20 patients with keratoconus (grades 2–4) underwent CAIRS implantation combined with accelerated corneal collagen cross-linking (CXL). The procedure involved femtosecond laser-assisted creation of intrastromal tunnels followed by insertion of custom-cut allogeneic segments. Key outcomes included significant improvements in uncorrected distance visual acuity (UDVA) of 2.79 ± 2.65 lines and corrected distance visual acuity (CDVA) of 1.29 ± 1.33.
Sources: en.wikipedia.org
=== Micro BCA assay (for dilute solutions) === The BCA Micro BCA assay is a 3-component protocol which uses concentrated stocks of the Biuret reaction, BCA, and copper(II) reagents. It allows for an improved sensitivity of ~2 - 40 μg/mL vs 20 - 2000 μg/mL of the original BCA assay. However, it has a different, and generally speaking more sensitive, interference from non-protein components. Kits for the Micro BCA assay are available from at least two commercial vendors. Notably, the composition and use of a "Micro BCA Reagent and Protocol" was described in the original manuscript by Smith, and modern kits likely consist of an exact or highly similar formulation. The protocol consists of mixing Micro-Reagent B and the Copper Solution 25:1 to form Micro-Reagent C (MC), which is not shelf stable and should be freshly prepared, and then mixing MC 1:1 with Micro-Reagent A to produce the final (also unstable) assay working solution. Micro-Reagent A, Micro-Reagent B, and Copper Solution are stable indefinitely at room temperature. Micro-Reagent A (MA)
=== Machine learning and statistics === In machine learning, one-hot encoding is a frequently used method to deal with categorical data. Because many machine learning models need their input variables to be numeric, categorical variables need to be transformed in the pre-processing part.
== Tissue distribution == Neutrophils and monocytes / macrophages are important source of S100A12 in the cell although some epithelial cells and dendritic cells are capable of its secretion. Some tissues are rich in these cells, and so in this protein. These include the spleen or lungs. It occurs intracellularly but is also produced into the extracellular environment where it occurs as a homodimer or hexamer.
Sources: en.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide coordinates the metal through its histidine imidazole, terminal amino group, and amide nitrogen. It is studied in biochemistry and dermatological research.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low and vary with physiological state. Its natural functions are not fully established.
Copper binding changes the peptide's charge, shape, and reactivity. The complex can participate in redox chemistry and interact with proteins differently than the free peptide. These differences are why studies specify whether they used GHK or GHK-Cu.
The peptide is glycyl-L-histidyl-L-lysine, a three-amino-acid sequence commonly abbreviated GHK. It binds a single copper(II) ion under typical laboratory conditions. The free peptide and the copper complex are separate chemical species with different properties.